Amgen Completes Acquisition of Alantos
Acquisition of Dipeptidyl Peptidase IV Inhibitor for Treatment of Type II Diabetes and Matrix Metalloproteinases Platform for OsteoarthritisTHOUSAND OAKS, Calif., Jul 16, 2007 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) today announced the completion of its
acquisition of Alantos, a private company developing drugs for the
treatment of diabetes and inflammatory diseases. The transaction
provides Amgen with Alantos's DPP-IV inhibitor in clinical development
(Phase 2a) for the treatment of type II diabetes as well as its matrix
metalloproteinases platform for osteoarthritis. The acquisition was
originally announced June 6.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe,
effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a deep and broad pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
Amgen, Thousand Oaks
Anne McNickle, 805-447-5890
Arvind Sood, 805-447-1060 (investors)